Fig 3.

Repeated dosing of the ZA/CG gel offers protection against vaginal SHIV-RT infection for up to 24 h. ZA/CG (n = 7) or CG (n = 3 real-time controls that have been added to 16 historical controls; n = 19) was applied daily for 14 days to depo-treated macaques before they were challenged vaginally with 10³ TCID₅₀ SHIV-RT 24 h later. (A) Plasma viral loads were measured over time (SIV RNA copies/ml of plasma), and each symbol denotes an individual animal. (B) Means (± SEM) of SIV RNA copies/ml for the animals that became infected in the two groups. (C) Percent infection in each of the different treatment groups: modified (mod) data, prototype (proto) data, and the combined data from the modified and prototype (mod/proto) ZA/CG groups versus the CG group are shown. The number of animals infected versus the number of animals challenged in each group is indicated above each bar.